1. Patients with Bipolar I Disorder

2. Patient informed of study and asked to participate

   Patient excluded

   NO

   YES

   3. Patient agreed to participate?

      YES

      3. Assessment of effectiveness and safety variables: Laboratory tests: lithium levels, serum valproate levels and carbamazepine-serum levels; variables related to the treatment’s safety through creatinine, liver transaminases, alkaline phosphatase and complete Blood Count, fasting glucose, TSH levels, T4 levels, weight, cholesterol. SF-36, YMRS, HRDS, CGI-BP-M, MG, and TOOL test

      NO

      4. Normal variables and meet inclusion criteria?

         YES

         Control group: usual care as well as written material and verbal information

         5. Randomization by study coordinator

         Intervention group: usual care as well as written material, verbal information, and Dader Method for pharmaceutical care

         6. \( t_0 \): Week 0: Appointment for written material and verbal information about MH and BD. Treatment adherence will be reinforced

         7. \( t_3 \): 3 months: Appointment to assess effectiveness and safety variables. Treatment adherence will be reinforced

         8. \( t_6 \): 6 months: Appointment to assess effectiveness and safety variables. Treatment adherence will be reinforced

         9. \( t_9 \): 9 months: Appointment to assess effectiveness and safety variables. Treatment adherence will be reinforced

         10. \( t_6 \): 12 months: Appointment to assess effectiveness and safety variables. Treatment adherence will be reinforced

         6. \( t_0 \): Week 0: Appointment for pharmaceutical care, written material and verbal information about MH and BD. Treatment adherence will be reinforced

         7. \( t_3 \): 3 months: Appointment for pharmaceutical care and assessment of effectiveness and safety variables. Treatment adherence will be reinforced

         8. \( t_6 \): 6 months: Appointment for pharmaceutical care and assessment of effectiveness and safety variables. Treatment adherence will be reinforced

         9. \( t_9 \): 9 months: Appointment for pharmaceutical care and assessment of the effectiveness and safety variables. Treatment adherence will be reinforced

         10. \( t_{12} \): 12 months: Appointment for pharmaceutical care and assessment of effectiveness and safety variables. Treatment adherence will be reinforced